Press Releases

- Study in the treatment of Dravet syndrome — a rare and severe form of epilepsy in children with no FDA-approved treatments - - Primary endpoint achieved with high statistical significance (p=0.01) showing that Epidiolex treatment reduces convulsive seizures in children compared to placebo - -

-Three Phase 3 Epidiolex clinical trials fully recruited above target sample size — on track for initial data in March 2016- -Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT- LONDON, Feb. 10, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the

LONDON, Feb. 04, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin

LONDON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 10 February,

LONDON, Dec. 24, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced

- Three Phase 3 Epidiolex Clinical Trials Fully Recruited Above Target Sample Size - on Track for Initial Data in Q1 2016 - - Significant Clinical Activity in Multiple Cannabinoid Pipeline Programs - - Conference Call Today at 4:30 p.m. EST , 9:30 p.m. GMT - LONDON , Dec.

As previously announced, seven posters relating to the physician sponsored Expanded Access Program for Epidiolex have been presented at the American Epilepsy Society Annual Meeting across Sunday, December 6 , and today Included within the information presented is new data issued in a poster

-Change to After Market on 7 December to Facilitate Inclusion of Additional Epidiolex Data-

LONDON , Nov. 25, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that seven

LONDON , Nov. 24, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin